Clinical trials: Aggressive
B Cell Lymphoma
Treatment of Aggressive Localized Lymphoma
Prospective and multicentric Phase III study, evaluation of the interest of the radiotherapy after 4 or 6 cycles of CHOP 14 R regimen of chemotherapy , patients with agressive and localized B lymphoma , age 18 to 75 years.
- Trial name
- NCT00841945
- Testing
- rituximab, doxorubicin, vincristine
- Where
- France
- Volunteers
- 334 people
- Sponsor
- French Innovative Leukemia Organisation
Impulsive Behavior, Compulsive Disorder
Treating Impulsivity in Adults With Probiotics
A multicentre randomized double-blind placebo controlled parallel design (10 weeks) study investigating probiotic supplementation in highly impulsive adults (18-65 yrs; N=180).
- Conditions
- Impulsive Behavior, Compulsive Disorder, ADHD, Borderline Personality Disorder
- Trial name
- PROBIA (NCT03495375)
- Testing
- Treatment with a probiotic
- Where
- 3 sites in Germany, Hungary and 1 more
- Volunteers
- 180 people
- Sponsor
- Hospital Vall d'Hebron
B-cell Lymphomas With MYC Rearrangement
Safety and Efficacy of Intensified Chemotherapy Regimens in Aggressive B-cell Lymphomas With MYC Rearrangement
A multicenter, retrospective, observational drug study using anonymized data from adult patients with aggressive B-cell lymphoma treated with the CARMEN regimen.
- Trial name
- OSR-CARMEN (NCT07663175)
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- IRCCS San Raffaele
High-risk Aggressive Lymphoma After Auto-HSCT
Maintenance Therapy Post-HSCT in High-risk Aggressive Lymphoma
Relapse after autologous hematopoietic stem cell transplantation (ASCT) is still challenging for high-risk aggressive lymphoma. This study was to investigate the efficacy and safety of maintenance therapy post-ASCT.
- Trial name
- NCT03695055
- Testing
- Maintenance therapy post-HSCT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fujian Medical University
Acute Coronary Syndromes, Dyslipidemia
Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome
This randomized clinical trial will evaluate whether starting bempedoic acid in addition to high-intensity statin therapy and ezetimibe within 72 hours after percutaneous coronary intervention improves low-density lipoprotein…
- Trial name
- EARLY-BIRD ACS (NCT07824323)
- Testing
- bempedoic acid, Ezetimibe, High-Intensity Statin Therapy
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- Taipei Medical University Hospital
Violent Aggressive Behavior, Mediation
Impact of a Mediator for Patient Intake in Emergency Departments
Violence in the workplace is becoming a serious phenomenon in the contemporary world of work. Hospital staff, like any employee working in contact with the public, is particularly exposed to this violence.
- Trial name
- MEDIA (NCT03139110)
- Testing
- Presence of a mediator in the emergency departments
- Where
- 4 sites in France
- Volunteers
- 2,378 people
- Sponsor
- Hospices Civils de Lyon
Desmoid Tumor
Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects of imatinib mesylate and to see how well it works…
- Trial name
- NCT00287846
- Testing
- imatinib mesylate
- Where
- 23 sites in France
- Volunteers
- 40 people
- Sponsor
- UNICANCER
Bullying
KiVa Anti-bullying Program in Chile: Evaluation of Effectiveness With and Without the Digital Game Component
Bullying is a major problem worldwide and, with no exception, in Chile. Bullying is defined as a systematic aggressive behavior against a victim who cannot defend himself or herself.
- Trial name
- KiVa-Chile (NCT02898324)
- Testing
- KiVa program
- Volunteers
- 4,485 people, healthy volunteers welcome
- Sponsor
- Universidad de los Andes, Chile
Alzheimer's Disease
Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease
This study evaluates the effect of ORM-12741 on agitation/aggression symptoms in Alzheimer's disease. Two thirds of the patients will receive ORM-12741 and one third will receive placebo.
- Trial name
- Nebula (NCT02471196)
- Testing
- ORM-12741
- Where
- Finland
- Volunteers
- 308 people
- Sponsor
- Orion Corporation, Orion Pharma
Diffuse Large B-Cell Lymphoma
Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
Evaluation of impact of metformin on 2 year progression-free survival (PFS) rate in subjects with previously untreated DLBCL when added to standard induction therapy. (R-CHOP)
- Trial name
- DLBCL (NCT02531308)
- Testing
- Metformin, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Rush University Medical Center
Juvenile Idiopathic Arthritis
Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis
The objective of this study is to compare in very early polyarticular juvenile idiopathic arthritis (JIA) the efficacy, safety, and cost-benefit-ratio of three treatment strategies: biologic combination, combination of…
- Trial name
- ACUTE-JIA (NCT01015547)
- Testing
- Infliximab plus methotrexate, Combination of DMARDs, Methotrexate alone
- Where
- 6 sites in Finland
- Volunteers
- 60 people
- Sponsor
- Helsinki University Central Hospital
Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
This phase II trial studies how well vorinostat and combination chemotherapy before donor stem cell transplantation work in treating patients with aggressive B-cell or T-cell non-Hodgkin lymphoma that has come back (relapsed).
- Conditions
- Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04220008
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Clofarabine
- Sponsor
- M.D. Anderson Cancer Center
Attention Deficit Disorder With Hyperactivity
Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)
This study will determine the advantages and disadvantages of adding one of two different types of drugs to stimulant treatment for reducing aggressive behavior in children with attention deficit with hyperactivity disorder…
- Trial name
- NCT00794625
- Testing
- Valproate, Risperidone, Stimulant medication
- Where
- 3 sites in United States
- Volunteers
- 270 people
- Sponsor
- Joseph Blader
Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Relapsed or Refractory B-cell Lymphoma
Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas
This prospective, single-center, open-label study evaluates a short course of CD20×CD3 bispecific antibody-based holding or bridging therapy before CD19-directed CAR T-cell therapy in adults with relapsed or refractory aggressive…
- Trial name
- NCT07883135
- Testing
- Glofitamab, Epcoritamab, Polatuzumab Vedotin
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- National Research Center for Hematology, Russia
Herniated Disc
Conservative Versus Aggressive Discectomy for Primary Disc Herniation With Radiculopathy
Summary: This is a prospective randomize study to compare conservative and aggressive discectomy for treatment of disc herniation with radiculopathy.
- Trial name
- NCT01204008
- Testing
- conservative discectomy, aggressive discectomy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Aggressive Periodontitis
Adjunctive Systemic Administration of Moxifloxacin in the Treatment of Aggressive Periodontitis
The adjunctive use of systemically administered antibiotics has been shown to provide a better clinical outcome, particularly in terms of probing depth (PD) reduction and attachment-level gain than SRP in subjects with Aggressive…
- Trial name
- NCT02125812
- Testing
- scaling and systemic moxifloxacin, scaling and root planing
- Where
- Colombia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Facultad Nacional de Salud Publica
Non-Hodgkin's Lymphoma
Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas
The current standard treatment for non-Hodgkin's lymphoma involves drugs called cyclophosphamide, doxorubicin, vincristine, prednisone and rituxan in a regimen called "R-CHOP." Using R-CHOP therapy, complete disappearance of…
- Trial name
- NCT00184002
- Testing
- Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Southern California
Lymphoma
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00032019
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 81 sites in United States, Puerto Rico
- Volunteers
- 78 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Autism
Oxcarbazepine Versus Placebo in Childhood Autism
The proposed study is designed to assess the effectiveness of treatment with Oxcarbazepine vs. placebo in childhood/adolescent autism.
- Trial name
- NCT00467753
- Testing
- Oxcarbazepine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Dental Implants, Aggressive Periodontitis
Impact of Periodontitis Grading on Peri-Implant Clinical and Bone Health: A 60-Month Prospective Study
This prospective cohort study evaluated the effect of periodontitis grading on peri-implant clinical and radiographic outcomes over a 60-month follow-up.
- Conditions
- Dental Implants, Aggressive Periodontitis, Chronic Periodontitis, Staging
- Trial name
- NCT07671456
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Campinas, Brazil